RNS Number : 7131Z
  Celsis International PLC
  23 July 2008
   

    Stock Exchange announcement
    FOR release: Wednesday 23 July 2008


    CELSIS INTERNATIONAL PLC
    ("Celsis", "the Company" or "the Group")

    Results of AGM


    23 July 2008: At the Annual General Meeting of Celsis, held today, all resolutions were duly passed.



 Enquiries:

 Celsis International plc                 Tel: +44 (0) 1223 598 428
 Jay LeCoque, Chief Executive Officer
 Jenny Woolway, Corporate Communications

 Financial Dynamics                       Tel: +44 (0) 20 7831 3113
 David Yates
 Jonathan Birt

    Notes to editors
    Celsis International plc  
    Celsis International plc is a leading international provider of innovative life science products and laboratory services to the
pharmaceutical and consumer products industries. Each Celsis division has the capacity to deliver substantial time and cost savings to its
customers, in addition to ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's
leading pharmaceutical and consumer products companies. The Company is listed on the London Stock Exchange (CEL.L).

    Celsis Rapid Detection division utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and
consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide
significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market. 

    Celsis Analytical Services division provides cost effective outsourced laboratory testing services to pharmaceutical companies. Its
comprehensive service offerings include a full spectrum of laboratory services from drug development and discovery to analytical chemistry
and biological sciences to stability storage and testing. 

    Celsis In Vitro Technologies (Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing
products to the pharmaceutical industry. Celsis IVT's consumable testing products screen drug compounds for liver toxicity early in the drug
discovery process, thereby reducing the time and cost of further development or trial on those compounds which will not be properly
metabolised by the human liver. 

    Further information can be found on its website at www.celsis.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
RAGFKNKNDBKDDOB
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Celadon Pharmaceuticals Charts.
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Celadon Pharmaceuticals Charts.